Ganaxolone + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout Ganaxolone + Placebo
Ganaxolone + Placebo is a phase 2 stage product being developed by Brain Biotech for PTSD. The current trial status is completed. This product is registered under clinical trial identifier NCT01339689. Target conditions include PTSD.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01339689 | Phase 2 | Completed |
Competing Products
11 competing products in PTSD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYN117 (nepicastat) + Placebo comparator | Johnson & Johnson | Phase 2 | 52 |
| Quetiapine + Placebo | Johnson & Johnson | Approved | 85 |
| Lu AG06466 + Placebo | Lundbeck | Phase 1 | 30 |
| Mifepristone 1200 mg daily + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| TNX-102 SL | Tonix Pharmaceuticals | Phase 2 | 44 |
| TNX-102 SL 5.6 mg | Tonix Pharmaceuticals | Phase 3 | 69 |
| TNX-102 SL + Placebo | Tonix Pharmaceuticals | Phase 2 | 44 |
| TNX-102 SL + Placebo SL Tablet | Tonix Pharmaceuticals | Phase 3 | 69 |
| TNX-102 SL + Placebo | Tonix Pharmaceuticals | Phase 2 | 44 |
| TNX-102 SL + Placebo SL Tablets | Tonix Pharmaceuticals | Phase 3 | 69 |
| TNX-102 SL | Tonix Pharmaceuticals | Phase 3 | 69 |